This inventor holds 1 USPTO granted patent and 4 published patent applications and 3 EPO patents. Top assignee: Aventis Pharma S.a.. Active years: 2002.
Company Filing History:
Years Active: 2002
Title: Innovations of Philippe Gabriel Steg in Gene Therapy
Introduction: Philippe Gabriel Steg is an esteemed inventor based in Paris, France, recognized for his groundbreaking contributions to medical science. With a focus on gene therapy, he has pioneered methods that look to improve patient outcomes in the treatment of restenosis.
Latest Patents: Philippe Gabriel Steg holds one notable patent titled "Gene therapy for restenosis using an adenoviral vector." This innovative method involves delivering a recombinant suicide-gene-containing adenovirus as a means of treating restenosis through gene therapy. His work in this area underscores the potential of genetic solutions in addressing significant health challenges.
Career Highlights: Steg is currently associated with Aventis Pharma S.A., a leading pharmaceutical company where he applies his expertise in research and development. His career showcases a commitment to advancing therapeutic techniques in the medical field.
Collaborations: Throughout his professional journey, Philippe has collaborated with accomplished colleagues such as Didier Branellec and Jean-François Dedieu. These partnerships have enriched his research and fostered a collaborative environment that encourages innovation.
Conclusion: Philippe Gabriel Steg represents a vital force in the realm of gene therapy, particularly in developing treatments for restenosis. His patent and ongoing work at Aventis Pharma S.A. highlight the importance of innovation in medicine and the potential for treatments that can transform patient care.